The FDA recently approved a new therapy, Zusduri (mitomycin) from UroGen Pharma. Zusduri, an alkylating drug, is indicated for the treatment of adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
Zusduri is administered only by intravesical instillation once weekly for six weeks delivered directly into the bladder thereby eliminating the need for surgery. The medication targets low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). More than 59,000 U.S. patients yearly face this recurrent disease.
The company did not disclose pricing for Zusduri at the time of approval.
Similarly, no details as to distribution were released.
CLICK HERE to access prescribing information
UroGen’s Zusduri wins FDA’s blessing as first therapy for certain bladder cancer patients, despite negative adcomm vote
CLICK HERE to read the article
